Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized open-label active-controlled study of semaglutide injection in Chinese adults with obesity
CTR20250062Phase 3Completed
- Sponsor
- Apeloa Kangyu Pharmaceutical
- Start
- Feb 2025
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of semaglutide in obesity, Overweight, sponsored by Apeloa Kangyu Pharmaceutical. Started Feb 2025; status: completed.
02
Drugs
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on CTR20250062.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250062.